|Mr. Keith E. Murphy||Exec. Chairman & Principal Exec. Officer||397.18k||N/A||1972|
|Dr. Jeffrey N. Miner||Chief Scientific Officer||221.09k||N/A||1962|
|Mr. Thomas Einar Jurgensen J.D., MS||Gen. Counsel & Corp. Sec.||264.86k||N/A||1957|
|Mr. Thomas P. Hess CPA, MBA||Pres & CFO||N/A||N/A||1964|
|Mr. Steve E. Kunszabo||VP of Investor Relations & Corp. Communications||N/A||N/A||N/A|
Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. It is also developing in vivo liver tissues to treat end-stage liver, life-threatening, and orphan diseases. The company was incorporated in 2007 and is headquartered in Solana Beach, California.
Organovo Holdings, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.